Graves Disease Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Novartis, Sun Pharma, Pfizer, Roche, Abbott, Thermo Fisher

Graves Disease Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Novartis, Sun Pharma, Pfizer, Roche, Abbott, Thermo Fisher
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Graves Disease pipeline constitutes 10+ key companies continuously working towards developing 10+ Graves Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Graves Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Graves Disease Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graves Disease Market.


Some of the key takeaways from the Graves Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Graves Disease treatment therapies with a considerable amount of success over the years. 
  • Graves Disease companies working in the treatment market are TSHR Septerna, Cyclopeptides advanceCOR, EVOQ Therapeutics, Worg Pharmaceuticals, AV7 Limited, Novartis Pharmaceuticals, Immunovant Sciences GmbH, and others, are developing therapies for the Graves Disease treatment 
  • Emerging Graves Disease therapies in the different phases of clinical trials are- Research Program, WP-1302, K1-70, CFZ533, Batoclimab, and others are expected to have a significant impact on the Graves Disease market in the coming years.   
  • In March 2023, Immunovant Sciences GmbH has started a study named ‘An Open-label Extension Study for Participants Who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Evaluate the Effectiveness and Safety of Batoclimab in Treating Thyroid Eye Disease (TED).
  • In November 2022, Immunovant Sciences GmbH has launched a trial named ‘A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for Treating Individuals with Active Thyroid Eye Disease (TED).
  • In June 2022, Sling Therapeutics, Inc., a biopharmaceutical firm, initiated a Series A financing round of USD 35 million, primarily led by TPG’s The Rise Fund. The secured funds are intended to bolster a Phase 2b clinical trial assessing the effectiveness of the company’s experimental drug, linsitinib, in treating thyroid eye disease (TED). TED is more prevalent among women and commonly impacts individuals dealing with hyperthyroidism resulting from Graves’ disease.
  • In May 2022, Mindray introduced the TRAb assay, aimed at diagnosing and managing Graves’ disease. TRAb (thyrotropin receptor antibody) represents the pathogenic antibody linked to Graves’ disease and is recognized as a crucial serum biomarker crucial for its diagnosis


Graves Disease Overview

An autoimmune condition called Graves’ disease causes hyperthyroidism, or the widespread overactivity of the thyroid gland. In the US, it is the most typical cause of hyperthyroidism. It bears Robert Graves’ name, an Irish physician who almost 150 years ago described this type of hyperthyroidism.


Get a Free Sample PDF Report to know more about Graves Disease Pipeline Therapeutic Assessment-


Emerging Graves Disease Drugs Under Different Phases of Clinical Development Include:

  • Research Program: TSHR Septerna
  • Research Program: Cyclopeptides advanceCOR
  • Research Program: EVOQ Therapeutics
  • WP-1302: Worg Pharmaceuticals
  • K1-70: AV7 Limited
  • CFZ533: Novartis Pharmaceuticals
  • Batoclimab: Immunovant Sciences GmbH


Graves Disease Route of Administration

Graves Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular


Graves Disease Molecule Type

Graves Disease Products have been categorized under various Molecule types, such as

  • Monoclonal antibody
  • Small molecule
  • Peptide


Graves Disease Pipeline Therapeutics Assessment

  • Graves Disease Assessment by Product Type
  • Graves Disease By Stage and Product Type
  • Graves Disease Assessment by Route of Administration
  • Graves Disease By Stage and Route of Administration
  • Graves Disease Assessment by Molecule Type
  • Graves Disease by Stage and Molecule Type


DelveInsight’s Graves Disease Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Further Graves Disease product details are provided in the report. Download the Graves Disease pipeline report to learn more about the emerging Graves Disease therapies


Some of the key companies in the Graves Disease Therapeutics Market include:

Key companies developing therapies for Graves Disease are – Pfizer, F. Hoffmann-La Roche Ltd., Abbott, Thermo Fisher Scientific Inc., Jubilant Pharma Holdings Inc., Novartis, Sun Pharma, Institute of Isotopes Co. Ltd., bioMerieux SA, Horizon Therapeutics Ireland DAC, and others


Graves Disease Pipeline Analysis:

The Graves Disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Graves Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graves Disease Treatment.
  • Graves Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Graves Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graves Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Graves Disease drugs and therapies


Graves Disease Pipeline Market Drivers

  • Increasing prevalence of Graves Disease, increased public awareness about the treatment of Graves’ disease are some of the important factors that are fueling the Graves Disease Market.


Graves Disease Pipeline Market Barriers

  • However, high cost of the treatment, complications associated with the treatment and other factors are creating obstacles in the Graves Disease Market growth.


Scope of Graves Disease Pipeline Drug Insight    

  • Coverage: Global
  • Key Graves Disease Companies: TSHR Septerna, Cyclopeptides advanceCOR, EVOQ Therapeutics, Worg Pharmaceuticals, AV7 Limited, Novartis Pharmaceuticals, Immunovant Sciences GmbH, and others
  • Key Graves Disease Therapies: Research Program, WP-1302, K1-70, CFZ533, Batoclimab, and others
  • Graves Disease Therapeutic Assessment: Graves Disease current marketed and Graves Disease emerging therapies
  • Graves Disease Market Dynamics: Graves Disease market drivers and Graves Disease market barriers 


Request for Sample PDF Report for Graves Disease Pipeline Assessment and clinical trials


Table of Contents

1. Graves Disease Report Introduction

2. Graves Disease Executive Summary

3. Graves Disease Overview

4. Graves Disease- Analytical Perspective In-depth Commercial Assessment

5. Graves Disease Pipeline Therapeutics

6. Graves Disease Late Stage Products (Phase II/III)

7. Graves Disease Mid Stage Products (Phase II)

8. Graves Disease Early Stage Products (Phase I)

9. Graves Disease Preclinical Stage Products

10. Graves Disease Therapeutics Assessment

11. Graves Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Graves Disease Key Companies

14. Graves Disease Key Products

15. Graves Disease Unmet Needs

16 . Graves Disease Market Drivers and Barriers

17. Graves Disease Future Perspectives and Conclusion

18. Graves Disease Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States